IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models

Background Immunotherapy targeting GD2 is very effective against high-risk neuroblastoma, though administration of anti-GD2 antibodies induces severe and dose-limiting neuropathic pain by binding GD2-expressing sensory neurons. Previously, the IgG1 ch14.18 (dinutuximab) antibody was reformatted into...

Full description

Bibliographic Details
Main Authors: Miranda P Dierselhuis, Maaike Nederend, Jeanette H W Leusen, Mitchell Evers, Marco Jansen, Chilam Chan, Thomas Valerius, Friederike Meyer-Wentrup, Annelisa M Cornel, Marjolein C Stip, Karli R Reiding, Mirjam J Damen, Albert J R Heck, Sofia Koustoulidou, Ruud Ramakers, Gerard C Krijger, Remmert de Roos, Edouard Souteyrand, Mark de Boer, Geert van Tetering
Format: Article
Language:English
Published: BMJ Publishing Group 2023-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/7/e006948.full

Internet

https://jitc.bmj.com/content/11/7/e006948.full

Similar Items